UBS Group’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $394K | Buy |
|
|||||
|
2025
Q1 | $190K | Sell |
|
|||||
|
2024
Q4 | $244K | Sell |
|
|||||
|
2024
Q3 | $263K | Buy |
|
|||||
|
2024
Q2 | $237K | Sell |
|
|||||
|
2024
Q1 | $420K | Sell |
|
|||||
|
2023
Q4 | $328K | Buy |
|
|||||
|
2023
Q3 | $171K | Sell |
|
|||||
|
2023
Q2 | $370K | Buy |
|
|||||
|
2023
Q1 | $177K | Sell |
|
|||||
|
2022
Q4 | $362K | Buy |
|
|||||
|
2022
Q3 | $88K | Buy |
|
|||||
|
2022
Q2 | $80K | Sell |
|
|||||
|
2022
Q1 | $209K | Sell |
|
|||||
|
2021
Q4 | $935K | Buy |
|
|||||
|
2021
Q3 | $2.23M | Sell |
|
|||||
|
2021
Q2 | $14.5M | Buy |
|
|||||
|
2021
Q1 | $224K | Sell |
|
|||||
|
2020
Q4 | $442K | Buy |
|